HomeBMY • NYSE
add
Bristol-Myers Squibb Co
Previous close
$43.97
Day range
$43.29 - $44.23
Year range
$42.96 - $63.33
Market cap
88.62B USD
Avg Volume
15.63M
P/E ratio
17.57
Dividend yield
5.70%
Primary exchange
NYSE
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2025info | Y/Y change |
---|---|---|
Revenue | 12.27B | 0.56% |
Operating expense | 4.78B | -27.91% |
Net income | 1.31B | -22.02% |
Net profit margin | 10.68 | -22.44% |
Earnings per share | 1.46 | -29.47% |
EBITDA | 5.12B | -1.16% |
Effective tax rate | 25.96% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 13.60B | 104.46% |
Total assets | 94.68B | 0.03% |
Total liabilities | 77.19B | -0.50% |
Total equity | 17.49B | — |
Shares outstanding | 2.04B | — |
Price to book | 5.13 | — |
Return on assets | 11.04% | — |
Return on capital | 15.06% | — |
Cash Flow
Net change in cash
(USD) | Jun 2025info | Y/Y change |
---|---|---|
Net income | 1.31B | -22.02% |
Cash from operations | 3.92B | 68.40% |
Cash from investing | -473.00M | 64.14% |
Cash from financing | -1.84B | 54.36% |
Net change in cash | 1.74B | 157.14% |
Free cash flow | 4.70B | 80.99% |
About
Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. Wikipedia
Founded
1887
Headquarters
Website
Employees
34,100